Deferasirox for managing iron overload in people with myelodysplastic syndrome-Reference-Cited by-同舟云学术

Deferasirox for managing iron overload in people with myelodysplastic syndrome

Published:2014-10-28 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Meerpohl Joerg J¹,Schell Lisa K¹,Rücker Gerta²,Fleeman Nigel³,Motschall Edith²,Niemeyer Charlotte M⁴,Bassler Dirk⁵

Affiliation:

1. Medical Center - University of Freiburg; German Cochrane Centre; Berliner Allee 29 Freiburg Germany 79110

2. Medical Center - University of Freiburg; Center for Medical Biometry and Medical Informatics; Stefan-Meier-Str. 26 Freiburg Germany 79104

3. University of Liverpool; Liverpool Reviews & Implementation Group; 2nd Floor, Sherrington Buildings Ashton Street Liverpool UK L69 3GE

4. University Medical Center Freiburg; Pediatric Hematology & Oncology, Center for Pediatrics & Adolescent Medicine; Mathildenstrasse 1 Freiburg Germany 79106

5. University Hospital Zurich; Department of Neonatology; Frauenklinikstrasse 10 Zurich Switzerland

Publisher

Wiley

Subject

Pharmacology (medical)

Reference150 articles.

1. 2006-006147-31 An open multicenter clinical trial to evaluate the safety, tolerability and efficacy of Deferasirox (ICL670) in patients affected by Myelodysplastic syndrome and transfusional chronic hemosiderosis https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006147-31

2. Deferasirox chelation therapy in transfusion dependent MDS patients. Final report from the Gimema MDS0306 prospective trial;Angelucci;Blood,2012

3. Acute interstitial nephritis due to deferasirox: a case report;Brosnahan;Nephrology, Dialysis, Transplantation,2008

4. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes;Cermak;Leukemia Research,2013

5. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade ®, ICL670);Tucci;European Journal of Haematology,2007

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ferroptosis as an emerging target in sickle cell disease;Current Research in Toxicology;2024

2. Emerging Roles of the Iron Chelators in Inflammation;International Journal of Molecular Sciences;2022-07-20

3. Interplay Between Iron Overload and Osteoarthritis: Clinical Significance and Cellular Mechanisms;Frontiers in Cell and Developmental Biology;2022-01-14

4. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1–Risk Myelodysplastic Syndromes;Annals of Internal Medicine;2020-03-24

5. Olfactory Dysfunction in β Thalassemia Major Patients Treated With Iron-Chelating Agents;Ear, Nose & Throat Journal;2019-05-29